Press Release

HemoVoid™ Advances Study of Dried Blood Spot Proteomics

MONMOUTH JUNCTION, NJ, November 26, 2025– A poster presented at the 2025 Human Proteome (HUPO) World Congress, highlights the advantage of HemoVoid™ enrichment in proteomic study of dried blood cards. The poster was presented by researchers from the Centre for Proteome Research at University of Liverpool and entitled “HAEMOGLOBIN INTERFERENCE IN DRIED BLOOD SPOT PROTEOMICS FOR


CHRONIC KIDNEY DISEASE”.

The use of dried blood spots is an exciting prospect for longitudinal and at home sampling of pediatric kidney patients. Proteomics allows characterization of the blood proteome using liquid chromatography - mass spectrometry (LC-MS). However, the presence of high abundance proteins, such as hemoglobin, can mask low abundance proteins making biomarker discovery less likely. By establishing methods to eliminate hemoglobin from reconstituted dried blood spots, other key proteins can be identified in Chronic Kidney Disease (CKD) patients.

The poster states “Comparison of three haemoglobin depletion kits (Biotech Support Group), along with Top 14 (ThermoFisher), found that HemoVoid removed the highest proportion of haemoglobin (75.79% ± 7.9%), with the lowest level of variation, resulting in the highest number of identified proteins (545 ± 5).” Furthermore, this method was applied to dried blood spots from Stage V CKD patients on dialysis for proof of principle, 136 proteins were identified as being statistically different compared to the healthy controls. The HemoVoid™ workflow allowed for the identification of potential clinically relevant biomarkers in CKD patients receiving haemodialysis, using a starting volume of just 10 µL of blood, and avoiding additional venepuncture.

“We envision that dried blood cards will become a more prominent sample type for proteomic investigations, so it is very rewarding to read this poster as it is a great example of how bead-based enrichment, rather than top-14 depletion, can be so advantageous. The HemoVoid™ product used in this study is one of many beads derived from our unique NRicher™ surface chemistry platform. Not only did HemoVoid™ enrichment prove to increase coverage, but it also was able to differentiate a panel of proteins, some of which may become productive biomarkers. stated Dr. Swapan Roy, President and Founder of Biotech Support Group.

Link to download poster

For more information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

For more information of all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

For more information on our NRicher™ bead chemistry platform, visit:

https://www.biotechsupportgroup.com/category-s/340.htm

About Biotech Support Group LLC
Biotech Support Group develops innovative sample preparation technologies that address the emerging needs of proteomics, biomarker discovery, and personalized medicine. Flagship products include Cleanascite™ for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum protein depletion, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance, family specific, and targeted proteome enrichment. These products support translational research by simplifying workflows and improving sample quality for downstream analysis.

For Business Development Inquiries:
Matthew Kuruc
Phone: 732-274-2866
Email: [email protected]

Keywords: HemoVoid™, Hemoglobin depletion, Hemoglobin removal, chronic kidney disease (CKD), dried blood spot proteomics